ClinicalTrials.gg
CompletedNCT03722329Updated Jan 9, 2020

Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects

A Phase 1 interventional study of Eculizumab in Healthy, sponsored by Samsung Bioepis Co., Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-09.

Sponsored by Samsung Bioepis Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2019, 7 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is to evaluate PK, safety, tolerability, immunogenicity, and PD profiles of SB12, EU sourced Soliris, and US sourced Soliris in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Samsung Bioepis Co., Ltd. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Have a body weight between 70-95 kg and a between 20.0-29.9 kg/m²
  • Have systolic blood pressure (SBP) ≤ 140 and ≥ 90 mmHg, diastolic blood pressure (DBP) ≤ 95 and ≥ 45 mmHg, and pulse rate ≥ 40 and ≤ 100 beats per minute or assessed as not
  • Have physical examination and 12-lead results without clinically significant finding at Screening and Day -1 visits
  • Non-smoker or smoker whose daily smoking does not exceed 10 cigarettes, 3 cigars, or 3 pipes for at least 30 days prior to Screening visit. Subjects should agree to abstain from smoking while resident at the clinical study site.
  • Willing to receive vaccination against N. meningitidis at least 14 days prior to IP administration
  • Male subjects must be willing to abstain from sexual intercourse or willing to use a condom in addition to having their female partner use another form of unless their partner is infertile from the time of IP administration until 5 months after IP administration
  • Must be willing and able to comply with scheduled visits, treatment plan, clinical laboratory tests, and other study procedures including lifestyle considerations
  • Have competence in speaking, writing and comprehending the local language where the study is conducted

Exclusion criteria

Exclusion Criteria:

  • Have a history/presence of atopic allergy, allergic/hypersensitive reactions, or known or suspected clinically relevant drug to eculizumab or its
  • for IP or non-IP to be used in the study
  • History of N. meningitidis infection
  • Known or suspected hereditary or acquired complement deficiency
  • Clinically significant active infection within 28 days before IP administration
  • Any systemic or local infection, a known risk for developing sepsis and/or known active inflammatory condition
  • Have previously been exposed to eculizumab (Soliris and its biosimilar)
  • Previous treatment with a monoclonal antibody or fusion protein within 9 months prior to IP administration and/or have an evidence of immunogenicity from previous exposure to a monoclonal antibody or fusion protein
  • Have previously been exposed to an agent or biological agent (any other than a monoclonal antibody or fusion protein) within 120 days prior to IP administration
  • Any of the following abnormal laboratory values at Screening and Day -1 visits:

    1. Serum and/or aspartate transaminase ≥ 1.5 ×
    2. Serum C-reactive protein ≥ 10 mg/L
    3. Serum creatinine > 1.5 × ULN
    4. Whole blood cell count \< 3000/mm3, absolute lymphocyte count \< 800/mm3, and/or ≤ 1500/mm3
    5. Any other laboratory abnormalities assessed as clinically significant by the Investigator
  • Positive test result for surface antigen and/or hepatitis B core antibody, virus antibody, or at Screening
  • Surgery within 90 days prior to IP administration, and/or operation during study period
  • Average intake of alcoholic beverages of more than 21 units/week for males and 14 units/week for females
  • Drug abuse or a positive urinary drug screening result
  • Have any prescription medicine or over-the-counter medicines (except paracetamol) that might have an effect on the objectives of the study, within 14 days prior to IP administration
  • Donated >100 mL blood or plasma within 28 days prior to IP administration
  • Subject directly involved in the conduct of the clinical study
  • Vulnerable subjects
  • Pregnant or nursing (lactating) women
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    SB12

    SB12 (proposed eculizumab biosimilar)

    Drug: Eculizumab

  • Active comparator
    EU Soliris

    EU sourced Soliris (eculizumab)

    Drug: Eculizumab

  • Active comparator
    US Soliris

    US sourced Soliris (eculizumab)

    Drug: Eculizumab

Interventions

  • Eculizumab Injection. 300 mg, single dose

06

What researchers measure

Primary outcomes

  1. AUCinf

    Area under the concentration-time curve from time zero to infinity

    Time frame: Day 1 to Day 64

Secondary outcomes

  1. AUClast

    Area under the concentration-time curve from time zero to the last quantifiable concentration

    Time frame: Day 1 to Day 64

  2. Cmax

    Maximum observed serum concentration

    Time frame: Day 1 to Day 64

  3. Tmax

    Time to reach Cmax

    Time frame: Day 1 to Day 64

  4. Vz

    Volume of distribution during terminal phase

    Time frame: Day 1 to Day 64

  5. λz

    Terminal rate constant

    Time frame: Day 1 to Day 64

  6. T1/2

    Terminal half-life

    Time frame: Day 1 to Day 64

  7. Clearance

    Total body clearance

    Time frame: Day 1 to Day 64

  8. %AUCextrap

    Percentage of AUCinf due to extrapolation from time of last measurable concentration (Tlast) to infinity

    Time frame: Day 1 to Day 64

  9. Incidence of Treatment-Emergent Adverse Events

    Experience at least 1 treatment-emergent adverse event

    Time frame: Day 1 to Day 64

  10. Incidence of Serious Adverse Events

    Experience at least 1 serious adverse event

    Time frame: Day 1 to Day 64

  11. Incidence of ADA

    Incidence of anti-drug antibodies

    Time frame: Day 1 to Day 64

  12. Incidence NAb

    Incidence neutralising antibodies

    Time frame: Day 1 to Day 64

07

Study locations

1 site
  • PAREXEL International GmbH, Early Phase Clinical Unit - Berlin
    Berlin, 14050, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2018
First posted
Oct 26, 2018
StartActual
Nov 13, 2018
Primary completionActual
Mar 29, 2019
CompletionActual
Apr 8, 2019
Last update
Jan 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03722329
Responsible party
Sponsor
First posted
Oct 26, 2018
Start date
Nov 13, 2018
Primary completion
Mar 29, 2019
Completion
Apr 8, 2019
Last update
Jan 9, 2020

Study contacts

Rainard Fuhr, MD
principal investigator · PAREXEL International GmbH, Early Phase Clinical Unit - Berlin

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion